medigraphic.com
ISSN 0016-3813 (Print)

2012, Number 3

<< Back Next >>

Gac Med Mex 2012; 148 (3)

Stevens-Johnson syndrome and toxic epidermal necrolysis in children

Sotelo-Cruz N

Language: Spanish
References: 51
Page: 265-275
PDF size: 103.06 Kb.


ABSTRACT

The Stevens-Johnson syndrome (SJS) and the toxic epidermal necrolysis (TEN) are clinical conditions manifesting as adverse cutaneous reaction to drugs in majority of cases, constituting the same clinical spectrum, differing only in the severity of epidermolysis; both conditions are distinguished by their severity and extensiveness of skin lesions; it can also involve mucous membranes of eyes, respiratory, digestive and urogenital tracts. Two per 1,000,000 are affected annually, among them approximately 20% are children and both of them are considered as potentially fatal medical emergency conditions. Even though the condition was described 89 years ago, until now the exact pathophysiology has not been completely explained. An immune-mediated mechanism has been implicated in its origin, which involves cytotoxic lymphocytes, cytokines, Fas-ligand in keratinocyte apoptosis; genetic makers also has been identified in some racial groups (HLA-B*1520, HLA-B*5801) in relationship with specific susceptibility to certain drugs such as carbamazepine, allopurinol. In children there are no uniform criteria for classification of the skin lesions, neither for the treatment, however recently the authors describe better response of the patients with use intravenous immunoglobulin (IGIV).


REFERENCES

  1. Steven AM, Johnson FC. A new eruptive fever associates with stomatitis and ophthalmia; report of two cases in children. Am J Dis Child. 1922;24:526-33.

  2. Lyell A. Toxic epidermal necrolysis: an eruption resembling scalding of the skin. Br J Dermatol. 1956;68(11):355-61.

  3. Batsuji-Garin S, Rzany B, Stern RS, Shear NH, Naldi L, Rojeau JC. Clinical classification of cases of toxic epidermal necrolysis, Stevens-Johnson syndrome and erythema multiform. Arch Dermatol. 1993;129:92-6.

  4. Roujeau JC, Stern RS. Severe adverse cutaneous reaction to drugs. N Engl J Med. 1994;331(19):1272-85.

  5. Prendeville JS. Erythema multiform and Stevens-Johnson syndrome in children. Curr Opin Pediatr. 1991;3:673-7.

  6. Forman R, Koren G, Shear NH. Erythema multiform, Stevens-Johnson syndrome and toxic epidermal necrolysis in children: a review of 10 years’ experience. Drug Saf. 2002;25(3):965-72.

  7. Harr T, French LE. Toxic epidermal necrolysis and Stevens-Johnson syndrome. Orph J Rare Dis. 2010;5.39. doi10.1186/1750-1172-5-39.

  8. Ball R, Ball LK, Wise RP, Braun MM, Beeler JA, Salive ME. Stevens- Johnson syndrome and toxic epidermal necrolysis after vaccination: reports to the vaccine events reporting system. Pediatr Infect Dis J. 2001;20(2):219-23.

  9. La Grenade L, Lee L, Weaver J, et al. Comparison of reporting of Stevens- Johnson syndrome and toxic epidermal necrolysis, in association with selective COX-2 inhibitors. Drug Saf. 2005;28(10):917-24.

  10. Chan HL. Toxic epidermal necrolysis in Singapore, 1989 through 1993: incidence and antecedent drug exposure. Arch Dermatol. 1995;131(10):1212-3.

  11. Saiag P, Caumes E, Chosidow O, Revuz J, Rojeau JC. Drug-induced toxic epidermal necrolysis (Lyell syndrome) in patients infected with the human immunodeficiency virus. J Am Acad Dermatol. 1992;26(4): 567-74.

  12. Rotunda A, Hirsh RJ, Scheinfeld N, Weinberg JM. Severe cutaneous reaction associated with the use of human immunodeficiency virus medications. Acta Derm Venereol. 2003;83(1):1-9.

  13. Aydin F, Cokluk C, Sentruk N, Aydin K, Canturk MT, Turanli AY. Stevens-Johnson syndrome in two patients with cranial irradiation and phenytoin. J Eur Acad Dermatol Venereol. 2006;20(5):588-90.

  14. Mandelcorn R, Shear NH. Lupus-associated toxic epidermal necrolysis: a novel manifestation of lupus? J Am Acad Dermatol. 2003;48(4):525-9.

  15. Zakrewiski JL, Lentini G, Such U, et al. Toxic epidermal necrolysis differential diagnosis of an epidermolitic dermopathy in an hematopoietic stem cell transplant recipient. Bone Marrow Transplant. 2002;30(5): 331-3.

  16. Aihara Y, Ito S, Kobayashy Y, Aihara M. Stevens-Johnson syndrome associated with azithromycin, followed by transient reactivation of herpes simplex virus infection. Allergy. 2004;59(1):118.

  17. Mulvey JM, Padowitz A, Lindely-Jones M, Nickles R. Mycoplasma pneumoniae associated with Stevens-Johnson syndrome. Anaesth Intensive Care. 2007;35(3):414-7.

  18. Del Pozzo-Magana BR, Lazo-Langer A, Carleton B, Castro-Pastrana LI, Rieder MJ. A systematic review of the treatment of drug induced Stevens-Johnson syndrome and toxic epidermal necrolysis in children. J Popul Ther Clin Parmacol. 2011;18(1):e121-33.

  19. Ruiz-Maldonado R. Acute disseminated epidermal necrolysis types 1, 2 and 3, study of sixty cases. J Am Acad Dermatol. 1985;13(4):623-35.

  20. Saban J, Pais JR, Rodríguez JL, Boixeda D. Sjögren-like pluriglandular exocrine insufficiency after drug-induced toxic epidermal necrolysis. Postgrad Med J. 1991;67(784):195-7.

  21. Chung WH, Hung SI. Genetic markers and danger signals in Stevens-Johnson syndrome and toxic epidermal necrolysis. Allergology International. 2010;59(4):325-32.

  22. Lonjou C, Thomas L, Borot N, et al. A marker for Stevens-Johnson syndrome…: ethnicity matters. Pharmacogenomics J. 2006;6(4):256-8.

  23. Lonjou C, Borot N, Sekula P, et al. A European study of HLB in Stevens- Johnson syndrome an toxic epidermal necrolysis related to five high-risk drugs. Pharmacogenet Genomics. 2008;18(2):99-107.

  24. Chun WH, Hung SI, Yang YJ, et al. Granulysin is a key mediator for disseminated keratinocyte death in Stevens-Johnson syndrome and toxic epidermal necrolysis. Nat Med. 2008;14(12):1343-50.

  25. Posadas SJ, Padial A, Torres MJ, et al. Delayed reactions to drugs show levels of perforin, granzyme B, and Fas-L to be related to disease severity. J Allergy Clin Immunol. 2002;109(1)155-61.

  26. Fritsh PO, Ruiz-Maldonado R. Stevens-Johnson syndrome toxic epidermal necrolysis. In: Freedberg IM, Eisen AZ, Wolf K, eds. Fitzpatrick’s dermatology in general medicine. New York: McGraw-Hill; 1999. p. 636.

  27. Mockenhaupt M, Viboud C, Dunant A, et al. Stevens-Johnson syndrome and toxic epidermal necrolysis: assessment of medication risks with emphasis on recently marketed drugs. The EuropSCAR-study. J Invest Dermatol. 2008;128(1):35-44.

  28. Rzany B, Correio O, Kelly JP, Auquier A, Stern R. Risk of Stevens- Johnson syndrome and toxic epidermal necrolysis during first week of antiepileptic therapy: a case control study. Lancet. 1999;353(9171): 2190-4.

  29. Bastuji-Garin S, Fouchard N, Bertocci M, Rojeau JC, Revuz J, Wolkenstein P. SCORTEN: a severity of illness score for toxic epidermal necrolysis. J Invest Dermatol. 2000;115(2):149-53.

  30. Wetter DA, Camilleri MJ. Clinical, etiologic and histopathologic features of Stevens-Johnson syndrome during a 8 year period at mayo Clinic. Mayo Clin Proc. 2010;85(2):131-8.

  31. Sotelo-Cruz N, Hurtado-Valenzuela J, Rascón-Alcantar A. Síndrome de Stevens-Johnson. Informe de 7 casos. Bol Med Hosp Infant Mex. 2005;62(1):25-32.

  32. Wolkenstein P, Chosidow O, Flechet ML, et al. Patch testing in severe cutaneous adverse drug reactions, including Stevens-Johnson syndrome and toxic epidermal necrolysis. Contact Dermatitis. 1996;35(4): 234-6.

  33. Pichler WJ, Tilch J. The lymphocyte transformation test in the diagnosis of drug hypersensitivity. Allergy. 2004;59(8):809-20.

  34. Kano Y, Hirahara K, Mitsuyama Y, Takahasi R, Shiohara T. Utility of the lymphocyte transformation test in the diagnosis of drug sensitivity: dependence on its timing and the type of drug eruption. Allergy. 2007;62(12):1439-44.

  35. Beller A, Zaccaria L Kawabata T, Gerber BO, Pichler WJ. CD69 up regulation on T cells and as in vitro marker delayed-type drug hypersensitivity. Allergy. 2008;62(2):181-8.

  36. Zawodiank A, Lochmatter P, Yerly D, et al. In vitro detection of cytotoxic T and NK cells in a peripheral blood of patients with various druginduced skin disease. Allergy. 2009;65(3):376-84.

  37. Yun SJ, Choi MS, Piao MS, et al. Serum lactate dehydrogenase is a novel marker for the evaluation of disease severity in early stage of toxic epidermal necrolysis. Dermatology. 2008;217(3):254-9.

  38. Ramírez-González MD, Herrera-Enríquez M, Villanueva-Rodríguez LG, Castell- Rodríguez AE. Role of epidermal dendritic cells in drug-induced cutaneous adverse reactions. Handb Exp Pharmacol. 2009;188:137-62.

  39. Viard L, Wehrli P, Bullani R, et al. Inhibition of toxic epidermal necrolysis by blockade of CD95 with human intravenous immunoglobulin. Science. 1998;282(5388):490-3.

  40. Majumdar S, Mockenpaut M, Rojeau J, Twnsed A. Interventions for toxic epidermal necrolysis. Cochrane Database Syst Rev. 2002;4:CD0011435.

  41. Mangla K, Rastogi S, Goyal P, Sloanki RB, Rawl RC. Efficacy of low dose intravenous immunoglobulin in children with toxic epidermal necrolysis: an open uncontrolled study. Indian J Dermatol Venereol Leprol. 2005;71(6):398-400.

  42. Tristani-Firouzi P, Petersen MJ, Saffle JR, Morris SE, Zone JJ. Treatment of toxic epidermal necrolysis with intravenous immunoglobulin in children. J Am Acad Dermatol. 2002;47(4):548-52.

  43. Kühn-Córdova I, Ramírez-Bouchan D, Gamboa-Marrufo JD. Uso de inmunoglobulina intravenosa en el tratamiento de la necrólisis epidérmica tóxica y síndrome de Stevens-Johnson. An Pediatr. 2007;67(1):68-73.

  44. Worswik S, Cotliar J. Stevens-Johnson syndrome and toxic epidermal necrolysis: a review treatment options. Dermatologic Therapy. 2011;24(2):207-8.

  45. Sotelo-Cruz N. Síndrome de Stevens-Johnson y necrólisis epidérmica tóxica. Revisión de 10 casos. 2-0 Coloquio Internacional de Toxicología Clínica Hospital Juárez, SSA; 21-23 de septiembre, 2011; México, D.F. (datos no publicados).

  46. Gregory DG. Treatment of acute Stevens-Johnson syndrome and toxic epidermal necrolysis using amniotic membrane: a review of 10 consecutive cases. Ophthalmology. 2011;118(5):908-14.

  47. Spies M, Sanford AP, Aili Low JF, Wolf SE, Herndon DN. Treatment of extensive toxic epidermal necrolysis in children. Pediatrics. 2001;108(5):1162-8.

  48. Adzick NS, Kim SH, Bondoc CC, Quinby WC, Remensnyder JP. Management of toxic epidermal necrolysis in a patient a burn center. Am J Dis Child. 1985;139(5):499-502.

  49. Khalili B, Bahna S. Pathogenesis and recent therapeutic trends in Stevens- Johnson syndrome and toxic epidermal necrolysis. Ann Allergy Asthma Immunol. 2006;97(3):272-80.

  50. Ferrándiz-Pulido C, García-Fernández D, Domínguez-Sampedro P, García-Patos V. Stevens-Johnson syndrome and toxic epidermal necrolysis in children: a review of the experience with pediatrics patients in a university hospital. J Eur Acad Dermatol Venereol. 2011;25(10):1153-9.

  51. Finklestein Y, Soon GS, Acuna P, et al. Recurrence and outcomes of Stevens-Johnson syndrome and toxic epidermal necrolysis in children. Pediatrics. 2011;128(4):723-8.




2020     |     www.medigraphic.com